Ionis Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 6/6
Ionis Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 68% bzw. 28.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 66.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 48.3% betragen.
Wichtige Informationen
68.0%
Wachstumsrate der Gewinne
66.62%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 28.8% |
| Wachstumsrate der Einnahmen | 28.2% |
| Zukünftige Eigenkapitalrendite | 48.26% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 08 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Sep 04
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Summary Ionis Pharmaceuticals, Inc. faces significant setbacks after initial optimism, with shares dropping sharply from 52-week highs amid clinical and competitive disappointments. IONS’ blockbuster ambitions for WAINUA and TRYNGOLZA have diminished; WAINUA is now a niche hATTR-PN therapy, and TRYNGOLZA faces direct competition from Arrowhead’s plozasiran. Recent failed Phase 2/3 trials with partners AstraZeneca, Roche, and Biogen have eroded near-term growth prospects and market confidence. Despite a $2B cash position, IONS's path to cash flow breakeven in 2028 is now clouded by pipeline setbacks and intensifying competition. Read the full article on Seeking Alpha
Narrative-Update • Sep 03
IONS: Trial Setbacks And 2026 Launch Milestones Will Shape Balanced Outlook
Ionis Pharmaceuticals' updated analyst price target has shifted from about $80 to $61 as analysts weigh recent trial setbacks and competitive readthroughs against the company’s marketed products, late stage pipeline, and ongoing launch and regulatory milestones. Analyst Commentary Recent Street research on Ionis Pharmaceuticals shows a clear split between bullish and cautious voices.
Narrative-Update • Aug 20
IONS: Severe Hypertriglyceridemia Franchise Will Define 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been trimmed from $92.00 to $88.00 as analysts weigh a higher discount rate against updated revenue growth and margin assumptions following recent shifts in price targets and mixed trial outcomes. Analyst Commentary Recent Street research on Ionis Pharmaceuticals reflects a split view.
Narrative-Update • Aug 06
IONS: sHTG Launch And Late Stage Pipeline Will Support Future Earnings Power
Ionis Pharmaceuticals' updated analyst price target is now $114.18, with analysts pointing to revised expectations for higher revenue growth and profit margins, offset by a lower future P/E assumption and a slightly higher discount rate, following recent mixed trial outcomes and ongoing enthusiasm around the Tryngolza and sHTG opportunity. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a split view.Narrative-Update • Jul 23
IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.Narrative-Update • Jul 09
IONS: Severe Triglyceride Label Win Will Reshape 2026 Risk Reward Profile
Analysts have raised the Ionis Pharmaceuticals fair value estimate by about $3.94 to $104.86, citing updated price targets following the FDA approval of Tryngolza, as well as increased confidence in the company’s proprietary and partnered pipeline. Analyst Commentary Recent research on Ionis Pharmaceuticals clusters around the FDA approval of Tryngolza and its implications for valuation, execution risk and long term growth potential across the company’s proprietary and partnered pipeline.Narrative-Update • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Analyseartikel • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...Narrative-Update • Jun 11
IONS: Priority Review In Severe Triglycerides Will Drive 2026 Risk Reward Repricing
Analysts have lifted their average price target on Ionis Pharmaceuticals toward $115, reflecting renewed focus on the $3.5b-plus Tryngloza opportunity in severe hypertriglyceridemia and upcoming partnered Phase 3 readouts in 2026, while leaving the modeled fair value at about $100.92 as the discount rate and margin assumptions are fine tuned. Analyst Commentary Street research around Ionis Pharmaceuticals has centered on how much value to ascribe to Tryngloza and the broader pipeline, with recent work fine tuning price targets and risk assumptions rather than radically changing the fundamental narrative.Narrative-Update • May 28
IONS: Priority Review In Severe Triglycerides Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has moved from $96.73 to $100.92 as analysts factor in higher assumed revenue growth, a stronger profit margin profile, and a lower future P/E multiple, supported by a wave of higher price targets and fresh Buy initiations that highlight the potential of Tryngloza and upcoming partnered Phase 3 readouts. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has been active, with multiple firms adjusting price targets and launching new coverage.Analyseartikel • May 11
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...Narrative-Update • May 02
IONS: Priority FDA Reviews In 2026 Will Support Stronger Earnings Power
Analysts have nudged the Ionis Pharmaceuticals fair value estimate higher to $130 from $120, citing a series of price target increases across the Street and updated assumptions around growth, profitability, and future P/E levels. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has leaned constructive, with a cluster of bullish analysts lifting price targets and reinforcing a positive view on execution and long term growth potential, even as one firm trimmed its target.Analyseartikel • May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...Narrative-Update • Apr 18
IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile
Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.Narrative-Update • Apr 04
IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile
Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.Narrative-Update • Mar 20
IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook
Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.Narrative-Update • Mar 06
IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations
Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.Narrative-Update • Feb 19
IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile
Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.Narrative-Update • Feb 05
IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook
Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.Narrative-Update • Jan 22
IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis
Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.Narrative-Update • Jan 08
IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile
Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.Narrative-Update • Dec 24
IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook
Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.Narrative-Update • Dec 10
IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook
Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.Narrative-Update • Nov 26
IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.Narrative-Update • Nov 05
IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins
The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.Analyseartikel • Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) defied analyst predictions to release its third-quarter results, which were...Narrative-Update • Oct 22
Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.Narrative-Update • Oct 08
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.Narrative-Update • Sep 23
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,947 | 37 | -79 | 141 | 16 |
| 12/31/2027 | 1,382 | -314 | -336 | -192 | 23 |
| 12/31/2026 | 913 | -584 | -524 | -442 | 23 |
| 6/30/2026 | 874 | -565 | -568 | -496 | N/A |
| 3/31/2026 | 1,058 | -327 | -978 | -911 | N/A |
| 12/31/2025 | 944 | -381 | -326 | -269 | N/A |
| 9/30/2025 | 967 | -256 | -309 | -247 | N/A |
| 6/30/2025 | 944 | -268 | -282 | -231 | N/A |
| 3/31/2025 | 717 | -458 | -560 | -502 | N/A |
| 12/31/2024 | 705 | -454 | -551 | -501 | N/A |
| 9/30/2024 | 803 | -359 | -374 | -352 | N/A |
| 6/30/2024 | 813 | -366 | -375 | -346 | N/A |
| 3/31/2024 | 777 | -385 | -345 | -323 | N/A |
| 12/31/2023 | 788 | -366 | -336 | -308 | N/A |
| 9/30/2023 | 615 | -409 | -574 | -541 | N/A |
| 6/30/2023 | 631 | -309 | -493 | -456 | N/A |
| 3/31/2023 | 576 | -329 | -405 | -377 | N/A |
| 12/31/2022 | 587 | -270 | -294 | -274 | N/A |
| 9/30/2022 | 875 | 7 | 110 | 130 | N/A |
| 6/30/2022 | 849 | -28 | 82 | 98 | N/A |
| 3/31/2022 | 841 | -4 | 35 | 54 | N/A |
| 12/31/2021 | 810 | -29 | 13 | 31 | N/A |
| 9/30/2021 | 661 | -608 | -96 | -75 | N/A |
| 6/30/2021 | 688 | -550 | -59 | -30 | N/A |
| 3/31/2021 | 708 | -495 | -45 | -11 | N/A |
| 12/31/2020 | 729 | -444 | -5 | 36 | N/A |
| 9/30/2020 | 933 | 94 | 173 | 216 | N/A |
| 6/30/2020 | 940 | 145 | 165 | 213 | N/A |
| 3/31/2020 | 959 | 169 | N/A | 230 | N/A |
| 12/31/2019 | 1,123 | 281 | N/A | 346 | N/A |
| 9/30/2019 | 821 | 433 | N/A | 183 | N/A |
| 6/30/2019 | 799 | 402 | N/A | 170 | N/A |
| 3/31/2019 | 752 | 366 | N/A | 697 | N/A |
| 12/31/2018 | 600 | 277 | N/A | 603 | N/A |
| 9/30/2018 | 575 | -41 | N/A | 508 | N/A |
| 6/30/2018 | 548 | -38 | N/A | 563 | N/A |
| 3/31/2018 | 543 | 9 | N/A | 65 | N/A |
| 12/31/2017 | 514 | 19 | N/A | 174 | N/A |
| 9/30/2017 | 507 | 42 | N/A | 127 | N/A |
| 6/30/2017 | 499 | 52 | N/A | 122 | N/A |
| 3/31/2017 | 426 | -15 | N/A | 86 | N/A |
| 12/31/2016 | 373 | -60 | N/A | -112 | N/A |
| 9/30/2016 | 238 | -184 | N/A | -123 | N/A |
| 6/30/2016 | 176 | -227 | N/A | -111 | N/A |
| 3/31/2016 | 258 | -134 | N/A | -12 | N/A |
| 12/31/2015 | 284 | -88 | N/A | 21 | N/A |
| 9/30/2015 | 317 | 14 | N/A | 129 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IONS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.7%).
Ertrag vs. Markt: IONS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: IONS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: IONSDie Einnahmen des Unternehmens (28.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13.5% pro Jahr).
Hohe Wachstumseinnahmen: IONSDie Einnahmen des Unternehmens (28.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IONSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (48.3%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/10 13:24 |
| Aktienkurs zum Tagesende | 2026/09/10 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ionis Pharmaceuticals, Inc. wird von 43 Analysten beobachtet. 23 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Eliana Merle | Barclays |
| James Birchenough | Barclays |
| Huidong Wang | Barclays |